Dmg Blockchain Solutions News

The parties intend to commence negotiation of definitive documentation relating to CannaChain and the development of the supply chain management solution. Key terms such as ownership of the joint venture, fees and commissions have not been finalized at this stage. Development of the supply chain management solution will not commence until after final terms have been settled and definitive documentation has been executed.

About DMG Blockchain Solutions

DMG Blockchain Solutions Inc. is a full service blockchain and cryptocurrency company that manages, operates and develops end-to-end solutions to monetize the blockchain ecosystem. DMG intends to be the global leader in crypto mining hosting, Mining as a Service (MaaS), crypto mining, forensics and diversified blockchain platform development.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. ('Botanicals'), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms Inc., a partnership with Village Farms International Inc. that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:
Robert Hill, CFO
(800) 757 3536 Ext. #722

Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are 'forward-looking statements'.
We caution you that such 'forward-looking statements' involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, formation of the joint venture, development of a foundational blockchain-based supply chain management system and e-commerce marketplace and the use and benefits thereof, provision of total transparency and assurances for end consumers, ensuring adherence to Health Canada reporting requirements and the unhackable nature of the digital ledger.
The parties do not intend, and do not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, failure to negotiate and execute definitive agreements, the ability of the parties to reach agreement on key terms, failure to obtain necessary funding, development of the necessary technology, hacking and malicious software, intellectual property disputes, competition, regulatory compliance variations in market conditions; and other risk factors described in filings by Emerald Health Therapeutics Inc. with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
More articles issued by Emerald Health Therapeutics Inc.
More articles related to:
Company Announcement
Thinly traded DMG Blockchain (OTCQB:DMGGF) selects IBM (NYSE:IBM) Canada to help develop blockchain-based global supply chain management solutions for regulated products such as pharmaceuticals.
DMG Blockchain expects to spend about C$3M in the first year to develop the platform and up to C$10M over three years through hiring IBM's personnel.
Sees funding costs through existing cash on hand, revenue, and, if required, further financings or collaborations with other companies.
IBM will provide program managers, technical architects, full stack developers, data scientists, data engineers, and developers to work with DMG's blockchain development team.
Previously: DMG Blockchain Solutions reports Q2 results (May 30)

Dmg Blockchain Solutions Inc

Inc
Now read: The Enterprise Blockchain Land Grab: A Highly Competitive Growth Opportunity »
Try Seeking Alpha PREMIUM for unlimited analysis on DMGGF